Clinical Trials in Tennessee

Showing 3081-3100 of 9,675 trials

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome

Vincerx Pharma, Inc.36 participantsStarted Sep 2023

Birmingham, Alabama, United States • Cincinnati, Ohio, United States • Nashville, Tennessee, United States +2 more locations

COMPLETEDPhase 1/229 miles

LEV102 Topical Gel in Acquired Blepharoptosis

NCT05715346

Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.

Acquired Blepharoptosis

Levation Pharma, Ltd.33 participantsStarted Feb 2023

Newport Beach, California, United States • Newport Beach, California, United States • Nashville, Tennessee, United States

TERMINATEDPhase 229 miles

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT01413750

Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving carboplatin and paclitaxel together is more effective with or without vorinostat in treating non-small cell lung cancer.

Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7

National Cancer Institute (NCI)23 participantsStarted Nov 2010

Duarte, California, United States • Los Angeles, California, United States • Sacramento, California, United States +10 more locations

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

LEV102 Topical Gel in Acquired Blepharoptosis

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Find Trials by Condition in Tennessee

Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

EnSite Precision Observational Study

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Pediatric Adenotonsillectomy Trial for Snoring

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)